FDA.MI - Fidia S.p.A.

Milan - Milan Delayed price. Currency in EUR
-0.18 (-2.15%)
At close: 5:36PM CET
Stock chart is not supported by your current browser
Previous close8.38
Bid7.16 x 30000
Ask7.78 x 18200
Day's range8.14 - 8.50
52-week range5.18 - 10.75
Avg. volume110,531
Market cap41.927M
PE ratio (TTM)N/A
EPS (TTM)-0.29
Earnings dateN/A
Forward dividend & yield0.20 (2.36%)
Ex-dividend date2017-07-03
1y target est7.25
  • Business Wire7 months ago

    FIDIA PHARMA USA Inc. Continues to Expand U.S. Presence as Fidia Farmaceutici S.p.A. Leads European Orthopedic Biomaterials Market

    Fidia Farmaceutici S.p.A., a world leader in the research, development and manufacturing of hyaluronan (HA)-based products, and its wholly owned subsidiary, FIDIA PHARMA USA Inc., are projecting continued growth in 2017. The global viscosupplementation market is anticipated to increase to over $2.64 billion by 2021, according to a research study by RnR Market Research1. Fidia Farmaceutici S.p.A. now leads the orthopedic biomaterials market in Europe after increasing its market share over the past few years.

  • We're sorry this is all we were able to find about this topic.

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes